These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 16092985)

  • 1. [A preliminary study on the serum HBsAg level in patients with chronic hepatitis B and hepatitis cirrhosis during lamivudine therapy].
    Qin LY; Liu KH; Zhang ZH; Wang YZ
    Zhonghua Gan Zang Bing Za Zhi; 2005 Aug; 13(8):602. PubMed ID: 16092985
    [No Abstract]   [Full Text] [Related]  

  • 2. Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with lamivudine.
    Kobayashi M; Suzuki F; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Yatsuji H; Kobayashi M; Suzuki Y; Arase Y; Ikeda K; Watahiki S; Iwasaki S; Miyakawa Y; Kumada H
    J Med Virol; 2007 Oct; 79(10):1472-7. PubMed ID: 17705186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison of lamivudine-induced HBsAg loss rate according to age in children with chronic hepatitis B].
    Kim JM; Choe BH; Chu MA; Cho SM
    Korean J Hepatol; 2009 Jun; 15(2):168-78. PubMed ID: 19581769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B.
    Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Kawamura Y; Kobayashi M; Kumada H
    J Med Virol; 2007 Sep; 79(9):1286-92. PubMed ID: 17607775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study on efficacy of lamivudine therapy in decompensated cirrhosis of liver due to chronic hepatitis B virus infection.
    Sharma YR; Miah AR; Saha SK; Mohammed S; Rahman M; Roy PK; Hasan M
    Nepal Med Coll J; 2004 Dec; 6(2):106-11. PubMed ID: 16295739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Loss or seroconversion of HBsAg in patients with chronic hepatitis B after treatment with lamivudine: 2 cases report].
    Zhao KK; Miao QL; Bi LN
    Zhonghua Gan Zang Bing Za Zhi; 2010 Nov; 18(11):871. PubMed ID: 21138644
    [No Abstract]   [Full Text] [Related]  

  • 7. Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome.
    Manolakopoulos S; Bethanis S; Elefsiniotis J; Karatapanis S; Triantos C; Sourvinos G; Touloumi G; Economou M; Vlachogiannakos J; Spandidos D; Avgerinos A; Tzourmakliotis D
    Aliment Pharmacol Ther; 2006 Mar; 23(6):787-95. PubMed ID: 16556181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis.
    Viganò M; Colombo M; Aroldi A; Lunghi G; Manenti E; Ponticelli C; Lampertico P
    Antivir Ther; 2005; 10(6):709-13. PubMed ID: 16218169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapeutic effect of lamivudine on liver fibrosis resulted from chronic hepatitis B].
    Tan XY; Hu SY
    Zhonghua Gan Zang Bing Za Zhi; 2003 Dec; 11(12):753. PubMed ID: 14697142
    [No Abstract]   [Full Text] [Related]  

  • 10. Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy for chronic hepatitis B.
    Borgniet O; Parvaz P; Bouix C; Chevallier P; Trépo C; André P; Zoulim F
    J Med Virol; 2009 Aug; 81(8):1336-42. PubMed ID: 19551826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients.
    Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Kao JH; Chen DS
    Liver Int; 2008 Aug; 28(7):1034-41. PubMed ID: 18492018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine.
    Vandepapelière P; Lau GK; Leroux-Roels G; Horsmans Y; Gane E; Tawandee T; Merican MI; Win KM; Trepo C; Cooksley G; Wettendorff M; Ferrari C;
    Vaccine; 2007 Dec; 25(51):8585-97. PubMed ID: 18031872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of lamivudine on cirrhotic patients following chronic hepatitis B].
    Lin XF; Lin XY; Han QX; Wang JH
    Zhonghua Gan Zang Bing Za Zhi; 2002 Aug; 10(4):304. PubMed ID: 12223149
    [No Abstract]   [Full Text] [Related]  

  • 14. A prospective and comparative cohort study on efficacy and drug resistance during long-term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis.
    Nishida T; Kobashi H; Fujioka S; Fujio K; Takaguchi K; Ikeda H; Kawaguchi M; Ando M; Araki Y; Higashi T; Shoji B; Takaki A; Iwasaki Y; Sakaguchi K; Shiratori Y; Yamamoto K
    J Gastroenterol Hepatol; 2008 May; 23(5):794-803. PubMed ID: 18086120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fatal liver failure with the emergence of hepatitis B surface antigen variants with multiple stop mutations after discontinuation of lamivudine therapy.
    Zhang JM; Wang XY; Huang YX; Yin YK; Guan S; Xu Y; Roggendorf M; Lu M
    J Med Virol; 2006 Mar; 78(3):324-8. PubMed ID: 16419112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early mortality in Taiwanese lamivudine-treated patients with chronic hepatitis B-related decompensation: evaluation of the model for end-stage liver disease and index scoring systems as prognostic predictors.
    Dai CY; Chuang WL; Hou NJ; Lee LP; Hsieh MY; Lin ZY; Chen SC; Huang JF; Hsieh MY; Wang LY; Tsai JF; Wen-Yu ; Yu ML
    Clin Ther; 2006 Dec; 28(12):2081-92. PubMed ID: 17296464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Predictive factors of hepatitis B virus DNA negative conversion among patients with chronic hepatitis B during lamivudine therapy].
    Chen JL; Wang L; Yan J; Zhang L; Yu H; Fan XL
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Sep; 21(3):273-5. PubMed ID: 17971944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to interferon-alpha in chronic hepatitis B patients with and without precore mutant strain and effects on HBsAg titers.
    Akhan SC; Yulugkural Z; Vahaboglu H
    Chemotherapy; 2007; 53(6):402-6. PubMed ID: 17934260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis.
    Schiff E; Simsek H; Lee WM; Chao YC; Sette H; Janssen HL; Han SH; Goodman Z; Yang J; Brett-Smith H; Tamez R
    Am J Gastroenterol; 2008 Nov; 103(11):2776-83. PubMed ID: 18721244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance.
    Hsu CW; Yeh CT; Chang ML; Liaw YF
    Gastroenterology; 2007 Feb; 132(2):543-50. PubMed ID: 17258721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.